5-108380777-T-G
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_001163315.3(FBXL17):āc.915A>Cā(p.Glu305Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000105 in 1,248,146 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Consequence
NM_001163315.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FBXL17 | NM_001163315.3 | c.915A>C | p.Glu305Asp | missense_variant | 1/9 | ENST00000542267.7 | NP_001156787.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FBXL17 | ENST00000542267.7 | c.915A>C | p.Glu305Asp | missense_variant | 1/9 | 1 | NM_001163315.3 | ENSP00000437464.2 | ||
FBXL17 | ENST00000518486.1 | n.187A>C | non_coding_transcript_exon_variant | 1/3 | 2 |
Frequencies
GnomAD3 genomes AF: 0.0000264 AC: 4AN: 151688Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000631 AC: 1AN: 15850Hom.: 0 AF XY: 0.000131 AC XY: 1AN XY: 7618
GnomAD4 exome AF: 0.000116 AC: 127AN: 1096458Hom.: 0 Cov.: 32 AF XY: 0.000122 AC XY: 63AN XY: 517878
GnomAD4 genome AF: 0.0000264 AC: 4AN: 151688Hom.: 0 Cov.: 32 AF XY: 0.0000270 AC XY: 2AN XY: 74088
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 10, 2024 | The c.915A>C (p.E305D) alteration is located in exon 1 (coding exon 1) of the FBXL17 gene. This alteration results from a A to C substitution at nucleotide position 915, causing the glutamic acid (E) at amino acid position 305 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at